Adynxx, Inc. Watch

from 10-Q/A 14 pages Indemnity Agreement

from 10-Q/A 12 pages B. Sublandlord Desires to Sublease the Entire Master Premises to Subtenant, and Subtenant Desires to Sublease the Entire Premises From Sublandlord, on the Terms and Conditions Contained in This Sublease. Hereinafter, the Master Premises Are Sometimes Referred to as the “Premises.” Now, Therefore, for Valuable Consideration, the Receipt and Sufficiency of Which Are Acknowledged, the Parties Agree as Follows: 1. Sublease of Premises

from 10-Q/A 11 pages Convertible Promissory Note

from S-1/A 39 pages Securities Purchase Agreement

from 10-Q 14 pages Indemnity Agreement

from 10-Q 12 pages B. Sublandlord Desires to Sublease the Entire Master Premises to Subtenant, and Subtenant Desires to Sublease the Entire Premises From Sublandlord, on the Terms and Conditions Contained in This Sublease. Hereinafter, the Master Premises Are Sometimes Referred to as the “Premises.” Now, Therefore, for Valuable Consideration, the Receipt and Sufficiency of Which Are Acknowledged, the Parties Agree as Follows: 1. Sublease of Premises

from 10-Q 11 pages Convertible Promissory Note

from S-1/A 28 pages Background

from 8-K 13 pages Adynxx, Inc. Stock Option Grant Notice

from 8-K 23 pages Adynxx, Inc. 2010 Equity Incentive Plan Adopted by the Board of Directors: December 8, 2010 Approved by the Stockholders: December 8, 2010 Termination Date: December 7, 2020

from 8-K 7 pages 1. Position and Salary. in Your Capacity as Chief Scientific Officer You Will Report to the Chief Executive Officer of Adynxx (The “CEO”). Your Annual Base Salary Will Be $266,990, Subject to Standard Payroll Deductions and Withholdings. You Will Also Be Eligible to Participate in Any Tax Qualified or Other Benefit Plans That May Be Offered by the Company. the Company Currently Makes an Annual Contribution to Each Employee’s 401(k) Retirement Plan Equal to Three Percent (3%) of Each Such Employee’s Annual Base Salary. Your Target Annual Bonus Will Be Thirty Percent (30%) of Your Annual Base Salary, Subject to Standard Payroll Deductions and Withholdings. the Amount of Your Awarded Bonus, Which May Be Above or Below the Target Amount Based on Company and Your Individual Performance, Will Be Based Upon Achievement of Milestones to Be Mutually Agreed Upon Between You and the CEO. Bonus Payments, if Any, Will Be Paid as Soon as Practicable Following the Determination by the Board of Directors of Adynxx (The “Board”) That the Bonus Has Been Earned, but in No Event After the Later of (I) March 15 Following the Calendar Year in Which Such Bonuses Are Earned or (II) the 15th Day of the 3rd Month Following the Close of Adynxx’s Fiscal Year in Which Such Bonuses Are Earned. 2. At-Will Employment; Severance

from 8-K 9 pages 1. Position and Salary. in Your Capacity as Chief Medical Officer You Will Report to the Chief Executive Officer of Adynxx (The “CEO”). Your Annual Base Salary Will Be $296,117, Subject to Standard Payroll Deductions and Withholdings. You Will Also Be Eligible to Participate in Any Tax Qualified or Other Benefit Plans That May Be Offered by the Company. the Company Currently Makes an Annual Contribution to Each Employee’s 401(k) Retirement Plan Equal to Three Percent (3%) of Each Such Employee’s Annual Base Salary (In Your Case, Currently Equal to $8,883 Per Annum). Your Target Annual Bonus Will Be Thirty-Five Percent (35%) of the Sum of Your Annual Base Salary Plus Any Annual Company Contribution to Your 401(k) Retirement Plan, Subject to Standard Payroll Deductions and Withholdings. the Amount of Your Awarded Bonus, Which May Be Above or Below the Target Amount Based on Company and Your Individual Performance, Will Be Based Upon Achievement of Milestones to Be Mutually Agreed Upon Between You and the CEO. Bonus Payments, if Any, Will Be Paid as Soon as Practicable Following the Determination by the Board of Directors of Adynxx (The “Board”) That the Bonus Has Been Earned, but in No Event After the Later of (I) March 15 Following the Calendar Year in Which Such Bonuses Are Earned or (II) the 15th Day of the 3rd Month Following the Close of Adynxx’s Fiscal Year in Which Such Bonuses Are Earned. 2. Stock

from 8-K 11 pages I Am Pleased to Offer You the Position of Chief Executive Officer of Adynxx, Inc. (“Adynxx” or the “Company”) Effective as of the Date of and Conditioned Upon the Initial Closing of a Qualified Financing (As Defined Below) With Gross Cash Proceeds (Excluding the Conversion of Any Promissory Notes Outstanding as of the Date Hereof) to the Company of at Least $4,000,000 (The ‘‘Initial Closing”). as Used Herein, a “Qualified Financing” Shall Mean a Preferred Stock Financing of the Company With the Principal Purpose of Raising Capital, Pursuant to Which the Company Agrees to Issue Shares of Its Series a Convertible Preferred Stock Resulting in Gross Cash Proceeds of at Least $12,000,000 in a Single Transaction; Provided, However, That a ‘‘Single Transaction” Shall Include a Transaction That Contemplates Multiple or Tranched Closings. in the Event of Multiple or Tranched Closings, the ‘‘Final Closing” Shall Mean the Closing That Results in Aggregate Gross Cash Proceeds to the Company (Including the Proceeds From All Prior Closings) of at Least $12,000,000. in the Event That the Initial Closing Does Not Occur on or Before February 28, 2011 (The “Outside Date”), This Employment Offer Is Withdrawn and Has No Effect. This Offer Letter Agreement (The “Agreement”) Sets Forth the Terms and Conditions of Your Employment With the Company

from 8-K 13 pages Alliqua Biomedical, Inc. Warrant to Purchase Stock

from 8-K 2 pages Amended and Restated Secured Promissory Note

from 8-K 4 pages Alliqua Biomedical, Inc. Lock-Up Agreement October 11, 2018

from DEFA14A 4 pages Alliqua Biomedical, Inc. Lock-Up Agreement October 11, 2018

from 8-K 4 pages General Release and Severance Agreement

from 8-K 4 pages General Release and Severance Agreement

from 8-K 4 pages General Release and Severance Agreement